12:00 AM
 | 
Aug 24, 2015
 |  BC Week In Review  |  Company News  |  Deals

Aveo Pharmaceuticals, Novartis deal

Aveo granted Novartis exclusive, worldwide rights to develop and commercialize AV-380 and related antibodies targeting growth differentiation factor 15 (GDF15). Novartis also...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD